HK1063726A1 - Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens - Google Patents

Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens

Info

Publication number
HK1063726A1
HK1063726A1 HK04106497A HK04106497A HK1063726A1 HK 1063726 A1 HK1063726 A1 HK 1063726A1 HK 04106497 A HK04106497 A HK 04106497A HK 04106497 A HK04106497 A HK 04106497A HK 1063726 A1 HK1063726 A1 HK 1063726A1
Authority
HK
Hong Kong
Prior art keywords
immunogenicity
pharmaceutical compositions
poorly immunogenic
immunogenic antigens
compositions enhancing
Prior art date
Application number
HK04106497A
Other languages
English (en)
Inventor
Luis Enrique Fernandez Molina
Belinda Sanchez Ramirez
Eduardo Raul Suarez Pestana
Anabel De La Barrera Aira
Cice Mesa Pardillo
Joel De Leon Delgado
Yildian Diaz Rodriguez
Rolando Perez Rodriguez
Original Assignee
Ct De Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Ct De Immunologia Molecular filed Critical Ct De Immunologia Molecular
Publication of HK1063726A1 publication Critical patent/HK1063726A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK04106497A 2000-12-06 2004-08-30 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens HK1063726A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
PCT/CU2001/000010 WO2002045746A2 (fr) 2000-12-06 2001-12-06 Compositions pharmaceutiques permettant d'augmenter l'immunogenecite d'antigenes peu immunogenes

Publications (1)

Publication Number Publication Date
HK1063726A1 true HK1063726A1 (en) 2005-01-14

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04106497A HK1063726A1 (en) 2000-12-06 2004-08-30 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens

Country Status (20)

Country Link
US (1) US7776342B2 (fr)
EP (1) EP1356822B1 (fr)
JP (1) JP4210519B2 (fr)
KR (1) KR100850473B1 (fr)
CN (1) CN1291755C (fr)
AR (1) AR031638A1 (fr)
AT (1) ATE485833T1 (fr)
AU (2) AU2002221519B2 (fr)
BR (1) BRPI0116013B8 (fr)
CA (1) CA2431188C (fr)
DE (1) DE60143363D1 (fr)
DK (1) DK1356822T3 (fr)
EA (1) EA005138B1 (fr)
HK (1) HK1063726A1 (fr)
MX (1) MXPA03005032A (fr)
NZ (1) NZ526282A (fr)
PE (1) PE20020572A1 (fr)
UY (1) UY27059A1 (fr)
WO (1) WO2002045746A2 (fr)
ZA (1) ZA200304411B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358910A1 (fr) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Procédés et moyens pour la prévention, inhibition et thérapie du cancer
EP1367395A1 (fr) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnostic des néoplasmes utilisant des anticorps anti-gangliosides
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
WO2005111079A2 (fr) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Immunogenes de vaccins vih et strategies d'immunisation, destines a eliciter des anticorps anti-hiv-1 a neutralisation large contre le domaine proximal de membrane de vih gp41
WO2010003219A1 (fr) * 2008-06-17 2010-01-14 Universite Laval Compositions contenant des porines de salmonelle et leurs utilisations comme adjuvants et vaccins
CA2822359C (fr) * 2010-12-22 2021-06-01 Bayer Intellectual Property Gmbh Reponse immunitaire accrue chez des especes bovines
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
CN111978409B (zh) * 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 自组装合成蛋白
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
US10087226B2 (en) * 2014-03-11 2018-10-02 Universite D'aix-Marseille Chimeric peptide that interacts with cell membrane gangliosides
US12019073B2 (en) * 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
EP3597214A1 (fr) 2017-03-15 2020-01-22 Centro de Inmunologia Molecular Méthode pour le traitement de patients présentant des carcinomes
CA3076012A1 (fr) * 2017-09-27 2019-04-04 L2 Diagnostics, Llc Compositions pharmaceutiques et vaccinales a base d'un peptide erbb et leurs utilisations therapeutiques pour le traitement du cancer
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
CA2139756A1 (fr) 1992-07-08 1994-01-20 Eric M. Bonnem Utilisation du gm-csf comme adjuvant vaccinal
CA2137638C (fr) * 1993-12-09 1999-07-20 Ana M. V. Lopez Anticoprs monoclonaux antigangliosides et leur emploi dans l'immunotherapie active specifique a des tumeurs malignes
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6207170B1 (en) * 1998-01-16 2001-03-27 Biomira U.S.A., Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Also Published As

Publication number Publication date
KR100850473B1 (ko) 2008-08-07
JP2004523494A (ja) 2004-08-05
CN1484532A (zh) 2004-03-24
WO2002045746A2 (fr) 2002-06-13
NZ526282A (en) 2005-01-28
DE60143363D1 (de) 2010-12-09
ZA200304411B (en) 2004-07-29
EA005138B1 (ru) 2004-12-30
PE20020572A1 (es) 2002-07-31
EA200300640A1 (ru) 2003-12-25
KR20030061838A (ko) 2003-07-22
JP4210519B2 (ja) 2009-01-21
ATE485833T1 (de) 2010-11-15
BRPI0116013B1 (pt) 2018-07-24
UY27059A1 (es) 2002-04-26
CA2431188A1 (fr) 2002-06-13
AU2151902A (en) 2002-06-18
AU2002221519B2 (en) 2006-11-23
US7776342B2 (en) 2010-08-17
WO2002045746A3 (fr) 2002-12-27
BRPI0116013B8 (pt) 2021-05-25
DK1356822T3 (da) 2011-02-07
CN1291755C (zh) 2006-12-27
MXPA03005032A (es) 2004-09-10
EP1356822A2 (fr) 2003-10-29
EP1356822B1 (fr) 2010-10-27
BR0116013A (pt) 2004-01-06
AR031638A1 (es) 2003-09-24
US20020136735A1 (en) 2002-09-26
CA2431188C (fr) 2010-09-07

Similar Documents

Publication Publication Date Title
HK1063726A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
IL151942A0 (en) Compositions and methods for enhancing immunogenicity of antigens
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
HUP0301413A3 (en) Vaccine compositions
HK1114781A1 (en) Multivalent vaccine composition
HUP0302117A3 (en) Vaccine composition
SI1150712T1 (sl) Pripravek cepiva proti humanem papiloma virusu
HUP0301697A3 (en) Oral solid dose vaccine
HUP0400445A3 (en) Novel vaccine composition
PL392363A1 (pl) Kompozycja szczepionki
AU2001280908A1 (en) Rotavirus vaccine formulations
EP1337149A4 (fr) Immunotherapie vaccinale pour patients immunodeprimes
GB0129007D0 (en) Adjuvanted antigenic meningococcal compositions
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
EP1490396A4 (fr) Peptides hiv immunogenes utilises en tant que reactifs et en tant que vaccins
AU2001267541A1 (en) Vaccine composition
AP2004003081A0 (en) Immunogenic formulations of variable peptidic epitopes and for preparation thereof
GB0105606D0 (en) Immunogens and vaccines and their preparation and use
GB9911823D0 (en) New vaccine formulations
GB0008029D0 (en) New vaccine formulations
GB0031218D0 (en) Metgod of vaccine preparation
GB9911825D0 (en) New vaccine formulations
GB9911824D0 (en) New vaccine formulations
GB9910537D0 (en) Therapeutic antibody, Immunogenic compositions and uses

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211205